ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

Pepper Committee, Impressed By Progress Reports, Promises Help With NCI Funding

June 29, 1979

Consensus Conference On Receptors Planned

June 22, 1979

In Brief: Interim Bill Keeps NCI Going Through Oct. 31; “Manual Fr Staging Of Cancer” Now Available

October 21, 1977

Firm Reports Limited Market For Self-Test Detection Methods

July 29, 1983